Literature DB >> 12483091

Laser peripheral iridoplasty as initial treatment of acute attack of primary angle-closure: a long-term follow-up study.

Jimmy S M Lai1, Clement C Y Tham, John K H Chua, Agnes S Y Poon, Dennis S C Lam.   

Abstract

PURPOSE: To study the long-term clinical course and complications of patients with acute primary angle-closure treated with immediate laser peripheral iridoplasty followed by laser peripheral iridotomy. PATIENTS AND METHODS: Consecutive patients with acute primary angle closure treated with immediate laser peripheral iridoplasty, followed by laser peripheral iridotomy, at the Prince of Wales Hospital from July 1997 through January 2000 were followed up to document the clinical course of their disease and any complications from the laser treatment. Visual acuity, intraocular pressure, gonioscopic findings, corneal and lens clarity, iris appearance, pupillary reaction, and progression of glaucomatous optic neuropathy were evaluated.
RESULTS: Thirty eyes of 29 Chinese patients with acute primary angle closure treated initially with either argon or diode laser peripheral iridoplasty were recruited. The mean follow-up period was 33.0 +/- 9.3 months. Twenty-one eyes (70%) had no further attack and maintained normal intraocular pressure without medications, and 9 eyes (30%) developed chronic angle-closure glaucoma with peripheral anterior synechiae. All eyes had pigmented laser marks on the peripheral iris, but none had peripheral corneal burn.
CONCLUSIONS: Long-term follow-up data indicated that 30% of Chinese eyes with acute primary angle closure successfully treated with immediate laser peripheral iridoplasty followed by laser peripheral iridotomy developed peripheral anterior synechiae and an increase in intraocular pressure. There were minimal long-term complications on the cornea and the lens from the laser treatment.

Entities:  

Mesh:

Year:  2002        PMID: 12483091     DOI: 10.1097/00061198-200212000-00005

Source DB:  PubMed          Journal:  J Glaucoma        ISSN: 1057-0829            Impact factor:   2.503


  8 in total

1.  Cyclodiode laser in the treatment of acute angle closure.

Authors:  A Manna; P Foster; M Papadopoulos; W Nolan
Journal:  Eye (Lond)       Date:  2012-02-03       Impact factor: 3.775

2.  Quantitative evaluation of changes in anterior segment biometry by peripheral laser iridotomy using newly developed scanning peripheral anterior chamber depth analyser.

Authors:  K Kashiwagi; K Abe; S Tsukahara
Journal:  Br J Ophthalmol       Date:  2004-08       Impact factor: 4.638

3.  Primary acute angle closure: long-term clinical outcomes over a 10-year period in the Chinese population.

Authors:  Jacky W Y Lee; Billy K T Wong; Doris W F Yick; Ian Y H Wong; Can Y F Yuen; Jimmy S M Lai
Journal:  Int Ophthalmol       Date:  2013-06-04       Impact factor: 2.031

4.  Diode laser transscleral cyclophotocoagulation followed by phacotrabeculectomy on medically unresponsive acute primary angle closure eyes: the long-term result.

Authors:  Wei Liu; Yanhui Chen; Yingjuan Lv; Linni Wang; Xiaoli Xing; Aihua Liu; Jian Ji
Journal:  BMC Ophthalmol       Date:  2014-03-10       Impact factor: 2.209

5.  Early phacoemulsification in patients with acute primary angle closure.

Authors:  Sasan Moghimi; Hesam Hashemian; Rebecca Chen; Mohammadkarim Johari; Massood Mohammadi; Shan C Lin
Journal:  J Curr Ophthalmol       Date:  2016-01-12

Review 6.  Lasers in glaucoma.

Authors:  Harsh Kumar; Tarannum Mansoori; Gazella B Warjri; Bindu I Somarajan; Suman Bandil; Viney Gupta
Journal:  Indian J Ophthalmol       Date:  2018-11       Impact factor: 1.848

7.  Efficacy of goniosynechialysis for advanced chronic angle-closure glaucoma.

Authors:  Guoping Qing; Ningli Wang; Dapeng Mu
Journal:  Clin Ophthalmol       Date:  2012-10-29

8.  Longitudinal Change in Peripheral Anterior Chamber Depth of Eyes with Angle Closure after Laser Iridotomy.

Authors:  Toshie Furuya; Kenji Kashiwagi
Journal:  J Ophthalmol       Date:  2018-12-24       Impact factor: 1.909

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.